HR means "hormone receptor." A plus sign (+) after HR means that your cancer cells have hormone (estrogen and/or progesterone) receptors. HR+ breast cancer uses hormones, like estrogen, to grow. HER2 is a protein found in healthy, normal cells. A minus sign (-) after HER2 means that your cancer cells have a small amount of HER2 or none at all. HR+, HER2- is the most common subtype of breast cancer. HR+, HER2- breast cancer that is metastatic means that the cancer has spread throughout the body to a distant location.

KISQALI is a prescription medicine used to treat adults with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative breast cancer that has gotten worse or has spread to other parts of the body (advanced or metastatic breast cancer), in combination with:

• an aromatase inhibitor as the first endocrine-based therapy, or

• fulvestrant as the first endocrine-based therapy or following disease progression on endocrine therapy

Click here to learn more about results with KISQALI.

KISQALI is a targeted treatment for HR+ (ER+ and/or PR+), HER2- metastatic breast cancer that blocks, or interferes with, substances that play a key role in cancer cell growth and survival. KISQALI affects cancer cells, but can also affect healthy cells.

Learn how KISQALI and hormone therapy or fulvestrant work together to help delay disease progression.

See the proven results of KISQALI + hormone therapy or fulvestrant.

Overall survival is about living with metastatic breast cancer. Learn how overall survival is different from progression-free survival.

The most common side effects of KISQALI are decreased white blood cell counts, decreased red blood cell counts, increased liver function tests, infections, nausea, increased kidney function test, tiredness, decreased platelet counts, diarrhea, vomiting, headache, constipation, hair loss, cough, rash, back pain, and low blood sugar level. KISQALI can also cause more serious side effects. Learn more about the potential side effects of KISQALI.

Although not all side effects can be managed, your health care team may offer suggestions to help manage some of the side effects of KISQALI. It’s important to talk with your doctor or nurse about side effects you experience and the best ways to manage them. Get tips about managing some common KISQALI side effects.

KISQALI is a prescription medicine that is a convenient once-daily oral tablet that comes in an easy-to-use blister pack. Your health care provider will prescribe the dose of KISQALI that's right for you. You should take KISQALI exactly as your health care provider tells you. Take KISQALI each day at about the same time, preferably in the morning. Do not change your dose or stop taking KISQALI unless your doctor tells you. You may take KISQALI with or without food. Ask your doctor about the recommended dose of your nonsteroidal aromatase inhibitor (NSAI) or fulvestrant. Learn more about taking KISQALI.

If you miss a dose of KISQALI or vomit after taking a dose of KISQALI, do not take another dose on that day. Take your next dose at your regular time.

Avoid eating grapefruit and avoid drinking grapefruit juice. Be sure to share a list of any medications, vitamins, or herbal supplements you are currently taking with your doctor. It's important to make sure all of your medications work safely together.

Novartis Pharmaceuticals Corporation is committed to helping make treatment with KISQALI as affordable as possible. Learn about Savings & Support.

Novartis Patient Support™ is a comprehensive program to help you start, stay, and save on your KISQALI treatment. Sign up for Novartis Patient Support.

Yes. The Novartis Patient Support program is completely free to those who have been prescribed KISQALI.

There are many organizations that can help with other aspects of metastatic breast cancer treatment, including travel, nutrition, and more. See the link below for more details.

Support for you